Cowen and Company Begins Coverage on Avalanche Biotechnologies (AAVL)
Equities research analysts at Cowen and Company started coverage on shares of Avalanche Biotechnologies (NASDAQ:AAVL) in a research note issued to investors on Monday. The firm set an “outperform” rating and a $45.00 price target on the stock. Cowen and Company’s price objective points to a potential upside of 47.44% from the company’s current price.
AAVL has been the subject of a number of other recent research reports. Analysts at Piper Jaffray initiated coverage on shares of Avalanche Biotechnologies in a research note on Monday. They set an “overweight” rating on the stock. Analysts at Jefferies Group initiated coverage on shares of Avalanche Biotechnologies in a research note on Monday. They set a “buy” rating and a $40.00 price target on the stock.
Avalanche Biotechnologies (NASDAQ:AAVL) opened at 30.52 on Monday. Avalanche Biotechnologies has a 1-year low of $22.00 and a 1-year high of $32.375. The stock’s 50-day moving average is $26.28 and its 200-day moving average is $26.28. The company’s market cap is $651.9 million.
Avalanche Biotechnologies, Inc (NASDAQ:AAVL) is a biotechnology company focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.